Overview
At a Glance
5-Amino-1MQ is a small molecule that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular energy metabolism and fat storage. Early preclinical research suggests it may increase NAD+ levels and promote fat cell metabolism, making it interesting for obesity and metabolic health. However, the evidence is limited to cell culture and animal studies — no human clinical trials have been published. It is sold as a research chemical and its safety profile in humans is unknown.
5-Amino-1MQ has no published human clinical trials. All efficacy data comes from mouse studies. It is classified as a research chemical and is not FDA-approved for any use. The information in this guide is provided for educational purposes based on preclinical research. No claims of human efficacy can be made.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule compound — not a peptide — that inhibits the enzyme nicotinamide N-methyltransferase (NNMT). Despite frequently appearing alongside peptides in the metabolic health and anti-aging space, it is structurally and mechanistically distinct: it is a quinolinium salt with a molecular weight of approximately 173 Da, far smaller than peptides like BPC-157 (~1,419 Da) or semaglutide (~4,114 Da).
The interest in 5-Amino-1MQ stems from research identifying NNMT as a key metabolic regulator. NNMT is an enzyme that methylates nicotinamide (a form of vitamin B3), consuming a methyl donor called SAM (S-adenosylmethionine) in the process. NNMT is overexpressed in white adipose tissue of obese individuals, where it appears to promote fat storage and reduce cellular energy expenditure. By inhibiting NNMT, 5-Amino-1MQ increases the availability of NAD+ (nicotinamide adenine dinucleotide) — a critical coenzyme involved in energy metabolism — and reduces the accumulation of metabolically inactive fat (Kraus et al., 2014).
The foundational research was conducted primarily by the laboratory of Qin Yan at the University of Texas Health Science Center. In diet-induced obese mice, treatment with 5-Amino-1MQ reduced body weight, decreased fat mass, lowered cholesterol, and shrank adipocyte (fat cell) size — without affecting food intake (Neelakantan et al., 2021).
These results are entirely from mouse studies. No Phase 1, Phase 2, or Phase 3 human clinical trials for 5-Amino-1MQ have been published in peer-reviewed journals. The compound is sold by research chemical suppliers and some compounding-adjacent vendors, but it has no regulatory pathway to market and no established human safety or efficacy profile.
Quick Facts
| Property | Details |
|---|---|
| Chemical class | Quinolinium salt (small molecule) |
| Molecular weight | ~173 Da |
| Target enzyme | Nicotinamide N-methyltransferase (NNMT) |
| Effect on NAD+ | Increases intracellular NAD+ by preventing its degradation via NNMT |
| Routes studied | Intraperitoneal injection (mice); oral (commercial products) |
| Human trials | None published |
| FDA approval | None |
| Classification | Research chemical |
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
How It Works
The NNMT Enzyme
Nicotinamide N-methyltransferase (NNMT) is a cytoplasmic enzyme that catalyzes the methylation of nicotinamide (vitamin B3) using SAM as a methyl donor. This reaction produces two products: 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). The enzyme is expressed throughout the body but is particularly abundant in the liver and adipose (fat) tissue (Kraus et al., 2014).
NNMT sits at a critical metabolic crossroads because it consumes two important cofactors:
- Nicotinamide — a precursor to NAD+, which is essential for hundreds of metabolic reactions including energy production, DNA repair, and sirtuin activation
- SAM — the universal methyl donor required for epigenetic regulation, neurotransmitter synthesis, and numerous biosynthetic pathways
NNMT and Obesity
Research has shown that NNMT is overexpressed in the white adipose tissue of obese individuals and obese mice. Elevated NNMT activity appears to:
- Deplete NAD+ in fat cells, reducing their capacity for energy expenditure
- Consume SAM, disrupting methylation-dependent metabolic pathways
- Promote a metabolically "sluggish" adipocyte phenotype that favors fat storage over fat oxidation
- Create a vicious cycle where excess fat drives more NNMT expression, which promotes more fat storage
The landmark study by Kraus et al. (2014) demonstrated that knocking down NNMT expression in white adipose tissue of mice (using antisense oligonucleotides) protected against diet-induced obesity, increased energy expenditure, and improved insulin sensitivity — without affecting food intake (Kraus et al., 2014).
How 5-Amino-1MQ Inhibits NNMT
5-Amino-1MQ is a competitive inhibitor of NNMT. It binds to the active site of the enzyme, preventing nicotinamide from being methylated. This produces a cascade of downstream metabolic effects (Neelakantan et al., 2021):
- Increased NAD+: By preventing nicotinamide degradation, more nicotinamide is available for conversion to NAD+ through the salvage pathway. NAD+ drives mitochondrial energy production and activates sirtuins (longevity-associated enzymes).
- Preserved SAM: By reducing NNMT-mediated SAM consumption, more SAM is available for beneficial methylation reactions involved in gene regulation and metabolic control.
- Enhanced energy expenditure: Increased NAD+ in adipocytes shifts their metabolism from fat storage toward fat oxidation, increasing cellular energy expenditure.
- Reduced adipocyte size: In mouse models, NNMT inhibition caused fat cells to shrink, reflecting increased lipolysis and reduced lipogenesis.
Go Deeper
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Research
Everything described below was observed in mice. Approximately 90% of compounds that show efficacy in animal models fail in human clinical trials. No human safety or efficacy data exists for 5-Amino-1MQ.
Foundational Research: NNMT as a Target
- Kraus et al. (2014) — Nature: This landmark paper established NNMT as a viable metabolic target. Using antisense oligonucleotides to knock down NNMT in white adipose tissue of diet-induced obese mice, the researchers demonstrated: reduced body weight gain, decreased fat mass, increased whole-body energy expenditure, and improved glucose tolerance — without changes in food intake. This study validated the concept that NNMT inhibition could treat obesity, but it did not use 5-Amino-1MQ specifically (Kraus et al., 2014).
5-Amino-1MQ Studies
- Neelakantan et al. (2021) — Biochemical Pharmacology: This is the primary published study of 5-Amino-1MQ as a pharmacological NNMT inhibitor. Diet-induced obese mice received 5-Amino-1MQ via intraperitoneal injection for 11 days. Key findings (Neelakantan et al., 2021):
- Significant reduction in body weight (approximately 7% decrease versus controls)
- Reduction in white adipose tissue mass and adipocyte (fat cell) size
- Decreased total cholesterol
- No change in food intake — weight loss was driven by increased energy expenditure, not appetite suppression
- No observed toxicity at the doses used
- Increased intracellular NAD+ levels in adipose tissue
Related NNMT Research
- NNMT and cancer: NNMT overexpression has been observed in several cancer types. Whether NNMT inhibition would help or harm cancer outcomes is an open research question (Hong et al., 2015).
- NNMT and aging: NAD+ depletion is associated with aging. NNMT inhibition as a strategy to maintain NAD+ levels is a theoretical anti-aging approach, but no longevity-specific studies of 5-Amino-1MQ have been published.
- Other NNMT inhibitors: 5-Amino-1MQ is not the only NNMT inhibitor under investigation. Multiple pharmaceutical and academic groups are developing NNMT inhibitors for metabolic disease, reflecting broad scientific interest in the target.
Limitations of the Research
- No human data. This cannot be overstated. There are no published human pharmacokinetic, safety, or efficacy studies.
- Mouse-to-human translation rate is low. Historically, approximately 90% of drugs that succeed in animal models fail in human trials — due to differences in metabolism, bioavailability, toxicity, or simply because the mechanism does not work the same way in humans.
- Route of administration differs. The published mouse study used intraperitoneal injection. Commercial products are sold as oral capsules. Oral bioavailability of 5-Amino-1MQ in humans has not been established.
- Short treatment duration. The primary study treated mice for 11 days. Long-term safety and efficacy — even in mice — has not been published.
- Single research group. Most of the primary 5-Amino-1MQ data comes from one laboratory. Independent replication is limited.
- No dose-response data in humans. Optimal dosing for humans is entirely unknown.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Uses
FDA Status
5-Amino-1MQ has no FDA-approved indication. It is not classified as a drug, dietary supplement, or approved biological product. It is sold as a research chemical. Any therapeutic use in humans is entirely experimental and unsupported by published clinical evidence.
How It Is Marketed
| Marketed Use | Evidence Basis | Notes |
|---|---|---|
| Fat loss / weight management | Mouse studies only | The primary marketing claim. Based on mouse data showing reduced body weight and fat mass. No human weight loss data exists. |
| NAD+ enhancement | Mechanistically plausible; mouse data | NNMT inhibition increases NAD+ availability in theory. Actual NAD+ changes in human tissues have not been measured with this compound. |
| Metabolic support | Extrapolated from mouse data | Cholesterol reduction and improved metabolic markers were observed in mice. Human metabolic effects are unknown. |
| Anti-aging / longevity | Theoretical only | Based on the NAD+-sirtuin connection in aging research. No longevity studies exist for 5-Amino-1MQ in any species. |
| Muscle preservation | Minimal preclinical suggestion | Some vendors claim muscle-preserving effects. Published evidence for this is absent or extremely limited. |
What 5-Amino-1MQ Is NOT
- Not a peptide: Despite being sold alongside peptides, 5-Amino-1MQ is a small molecule (~173 Da). It does not require injection and is not subject to peptide-specific degradation in the GI tract.
- Not a replacement for established obesity treatments: GLP-1 receptor agonists have Phase 3 data showing 15–25% weight loss. 5-Amino-1MQ has zero human weight loss data.
- Not an NMN or NR supplement: While 5-Amino-1MQ affects NAD+ through NNMT inhibition, it works through a completely different mechanism than NAD+ precursor supplements (NMN, NR). These approaches are not interchangeable.
- Not a dietary supplement: It does not have DSHEA (Dietary Supplement Health and Education Act) status. It is not legally marketed as a supplement in the United States.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Dosing
5-Amino-1MQ is a research chemical with no published human clinical trials. No safe or effective human dose has been established. The information below reflects what is sold commercially — it is NOT based on human clinical evidence. Do not use any research chemical without guidance from a qualified healthcare provider.
Commercially Available Dosing
| Route | Typical Dose | Frequency | Notes |
|---|---|---|---|
| Oral capsule | 50–150 mg | Once daily | Taken in the morning. Some vendors recommend with or without food. No published data supports either approach for humans. |
| Oral capsule (higher dose) | 100–150 mg | Once daily | Higher-dose products exist. No dose-response data in humans supports this range. |
Sources: Neelakantan et al. (2021) — dosing in mouse study, the only published preclinical data.
Why Mouse Dosing Does Not Translate Directly
The published mouse study administered 5-Amino-1MQ at 16.5 mg/kg via intraperitoneal injection. Directly scaling this to humans is problematic because:
- Mice have faster metabolic rates than humans — standard allometric scaling uses a conversion factor, not direct weight multiplication
- Intraperitoneal injection in mice delivers the compound directly to the peritoneal cavity with different absorption kinetics than oral dosing
- Oral bioavailability of 5-Amino-1MQ in humans has not been measured
- First-pass metabolism in the human liver may significantly reduce the amount reaching systemic circulation
Cycling
No evidence-based cycling protocol exists. Commercial vendors suggest various cycling patterns (e.g., 8 weeks on / 4 weeks off) based on convention, not data.
Storage
- Store at room temperature in a dry location, per manufacturer instructions
- Protect from moisture and direct sunlight
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Results: What Users Report
Unlike peptides with Phase 2 trial data (e.g., BPC-157 for IBD), 5-Amino-1MQ has zero published human data. User reports are the only human experience data available, and they are inherently unreliable for establishing causation. No controlled comparison to placebo exists in humans.
Reported Timeline
| Timepoint | What Users Typically Report |
|---|---|
| Week 1–2 | Some users report increased energy levels and mild appetite reduction. Others report no noticeable effects. |
| Week 2–4 | Users who report positive effects describe subtle body composition changes — reduced abdominal bloating, slight changes in how clothing fits. Weight scale changes are minimal. |
| Week 4–8 | Modest body composition improvements reported by some users. Weight loss, when reported, is typically 3–5 lbs over the full period — which could be entirely attributable to concurrent diet and exercise. |
| Week 8+ | Reports plateau or become inconsistent. No long-term user reports are systematically documented. |
Why User Reports Are Particularly Unreliable Here
- No baseline human data exists. Without clinical trials, there is no expected effect size, timeline, or mechanism confirmation in humans to compare against.
- Oral bioavailability is unknown. Users may be absorbing very little of the compound, making any reported effects potentially unrelated to 5-Amino-1MQ.
- Product quality is unverified. Research chemical products may not contain the labeled amount, may contain impurities, and have no regulatory quality standards.
- Strong placebo effect. Individuals who purchase a $100–$250/month research chemical and take it daily are psychologically primed to perceive improvement.
- Concurrent interventions: Most users of research compounds also make diet and exercise changes, making it impossible to isolate the compound's effect.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Side Effects
The side effect information below is compiled from user reports and extrapolated from preclinical data. No formal human safety assessment has been conducted. Unknown side effects — including potentially serious ones — may exist but have not been identified because no clinical monitoring has occurred.
User-Reported Side Effects
| Side Effect | Frequency (Anecdotal) | Notes |
|---|---|---|
| GI discomfort | Uncommon | Mild nausea, stomach upset, or loose stools reported by some users. May relate to the oral formulation rather than the active compound. |
| Headache | Uncommon | Mild and transient. Reported primarily in the first week of use. |
| Insomnia / restlessness | Rare | Some users report difficulty sleeping, possibly related to increased energy expenditure or stimulant-like effects. |
| Dizziness | Rare | Mild and transient. |
Note: These are user-reported observations, not findings from clinical trials. True incidence rates and causation are unknown.
Preclinical Safety Data
The published mouse study reported no observable toxicity at the doses used (16.5 mg/kg IP daily for 11 days). No changes in liver enzymes, kidney function, or hematological parameters were noted (Neelakantan et al., 2021). However, this was a short-duration study in a single species with a small sample size.
Theoretical Risks
- NNMT inhibition in non-adipose tissues: NNMT is expressed in the liver, brain, kidney, and other tissues — not only in fat. Inhibiting it systemically could have off-target effects in these organs that have not been characterized.
- SAM/methylation disruption: By preserving SAM levels in adipose tissue, NNMT inhibition could theoretically affect methylation balance in other tissues. The implications of this are unknown.
- Cancer considerations: NNMT is overexpressed in some cancers. Whether inhibiting NNMT helps or harms cancer outcomes is an active research question with no definitive answer (Hong et al., 2015).
- Drug interactions: No drug interaction studies have been conducted. Potential interactions with NAD+-modulating compounds (NMN, NR, niacin) or methylation-affecting medications are entirely unknown.
- Long-term effects: No data exists beyond 11 days of treatment in mice. Chronic NNMT inhibition in any species has not been studied.
Contraindications (Theoretical)
- Pregnancy and breastfeeding — no safety data
- Active cancer — due to uncertain role of NNMT in cancer biology
- Liver or kidney disease — NNMT is highly expressed in these organs; inhibition effects are unknown
- Children and adolescents — no data
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Regulatory Status
Current Classification
| Regulatory Body | Status |
|---|---|
| FDA | Not approved as a drug, not classified as a dietary supplement, not GRAS. No IND filed publicly. |
| DEA | Not a scheduled/controlled substance. |
| WADA | Not specifically listed, but may fall under S0 (non-approved substances) if used by athletes subject to testing. |
| International | Not approved as a therapeutic agent in any major regulatory jurisdiction. |
Research Chemical Classification
5-Amino-1MQ is sold as a "research chemical" — a designation that means:
- It is marketed as being intended for laboratory research, not human consumption
- Products typically carry disclaimers such as "not for human use" or "for research purposes only"
- No FDA manufacturing standards (cGMP) are required for research chemical production
- No purity, potency, or identity testing is mandated by any regulatory body
- The seller assumes no liability for human use
Despite these disclaimers, 5-Amino-1MQ is widely marketed and sold for human consumption through online vendors, sometimes alongside peptides and other research compounds. This represents a gap between regulatory classification and actual commercial practice.
Why No IND or Clinical Trials?
The absence of human clinical trials for 5-Amino-1MQ may reflect several factors:
- Commercial viability: As a small, relatively simple molecule, 5-Amino-1MQ may face challenges in obtaining patent protection, reducing commercial incentive for expensive clinical development.
- Competition: Established and well-funded NNMT inhibitor programs exist at pharmaceutical companies, potentially reducing interest in advancing this specific compound.
- Academic origin: The primary research group may lack the funding or infrastructure for clinical-stage development.
- Regulatory burden: Moving from a mouse study to human trials requires extensive preclinical toxicology, pharmacokinetics, and formulation work — representing millions of dollars in investment.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Cost
Typical Pricing
| Source | Typical Price Range | What You Get | Quality Assurance |
|---|---|---|---|
| Research chemical vendor | $100–$250/month | Oral capsules (50–150 mg), labeled "for research only." Typically 30–60 capsules per container. | Variable — some provide COAs (certificates of analysis); no regulatory quality standards apply. |
| Peptide/compounding vendor | $150–$250/month | Oral capsules, sometimes bundled with other compounds. May be marketed with health claims. | Variable — not subject to FDA pharmaceutical or supplement manufacturing standards. |
Insurance Coverage
5-Amino-1MQ is not covered by any insurance plan. As a research chemical with no approved indication, it cannot be billed under any benefit structure. All costs are out-of-pocket.
Cost-Effectiveness Consideration
Evaluating cost-effectiveness requires demonstrated efficacy — which does not exist for 5-Amino-1MQ in humans. For comparison:
| Treatment | Monthly Cost | Human Evidence for Weight Loss |
|---|---|---|
| 5-Amino-1MQ | $100–$250 | None (mouse data only) |
| NMN supplement | $30–$100 | Limited human data for NAD+ elevation; no weight loss trials |
| Semaglutide (Wegovy) | $300–$1,300 | Phase 3: ~15% body weight loss |
| Tirzepatide (Zepbound) | $400–$1,100 | Phase 3: ~20–25% body weight loss |
| Diet + exercise | $0–$100 | Well-established: 3–5% body weight loss typical |
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Questions & Answers
Myth: 5-Amino-1MQ is a peptide.
Answer: 5-Amino-1MQ is a small molecule — a quinolinium salt with a molecular weight of approximately 173 Da. Peptides are chains of amino acids, typically hundreds to thousands of daltons in weight. 5-Amino-1MQ contains no amino acids and has no peptide bonds. It is frequently grouped with peptides in marketing materials and vendor catalogs, but it is structurally and mechanistically a different class of molecule.
Myth: 5-Amino-1MQ is clinically proven to burn fat.
Answer: 5-Amino-1MQ reduced body weight and fat mass in diet-induced obese mice (Neelakantan et al., 2021). No human clinical trial has been published. "Clinically proven" requires human clinical evidence. Mouse efficacy data, while scientifically valuable, is not clinical proof. Approximately 90% of compounds that work in mice fail in human trials.
Myth: 5-Amino-1MQ boosts NAD+ like NMN.
Answer: Both 5-Amino-1MQ and NMN (nicotinamide mononucleotide) can theoretically increase NAD+, but through completely different mechanisms. NMN is a direct NAD+ precursor — it is converted to NAD+ through the salvage pathway. 5-Amino-1MQ inhibits NNMT, preventing the degradation of nicotinamide (which can then be converted to NAD+). These are distinct mechanisms with different tissue-specific effects, bioavailability profiles, and risk considerations. They are not interchangeable.
Myth: 5-Amino-1MQ has been proven safe for human use.
Answer: No human safety study has been published. The mouse study showed no toxicity at the doses tested over 11 days — this is encouraging but far from establishing human safety. NNMT is expressed in the liver, brain, kidneys, and other vital organs. The effects of chronic NNMT inhibition on these tissues in humans are unknown.
Myth: 5-Amino-1MQ is a legal supplement.
Answer: 5-Amino-1MQ does not meet the legal definition of a dietary supplement under DSHEA (Dietary Supplement Health and Education Act). It is not a vitamin, mineral, amino acid, herb, or substance with a history of dietary use. It is sold as a research chemical. Vendors who market it as a supplement may be doing so in violation of FDA regulations, though enforcement in this space is inconsistent.
Myth: If it works in mice, it will work in humans.
Answer: Drug development history demonstrates otherwise. The attrition rate from animal models to approved human therapies is approximately 90–95%. Differences in metabolism, receptor biology, bioavailability, and off-target effects mean that many compounds that show dramatic results in mice have no effect — or cause harm — in humans. The NNMT inhibition concept is scientifically sound, but whether 5-Amino-1MQ specifically will prove effective and safe in humans remains entirely unknown.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Key Takeaways
Based on the available evidence:
- 5-Amino-1MQ is a small molecule NNMT inhibitor, not a peptide. It is frequently miscategorized alongside peptides in marketing materials. It is a quinolinium salt that works by inhibiting the enzyme nicotinamide N-methyltransferase.
- The mechanism is scientifically legitimate. NNMT has been validated as a metabolic target by reputable research published in Nature and other high-impact journals. Inhibiting NNMT increased NAD+, reduced fat mass, and improved metabolic markers in mouse models (Kraus et al., 2014).
- All efficacy data is from mice. No Phase 1, Phase 2, or Phase 3 human clinical trials have been published. This is the most critical fact about 5-Amino-1MQ.
- Commercial availability has outpaced evidence. The compound is widely sold and marketed for human use despite having zero published human data. This represents a significant gap between evidence and commercial practice.
- Human safety is not established. Eleven days of mouse data does not constitute a safety profile. The effects of chronic NNMT inhibition on the liver, brain, kidneys, and other NNMT-expressing tissues are unknown in humans.
- Oral bioavailability is unknown. The published study used intraperitoneal injection in mice; commercial products are oral capsules. Whether effective amounts reach target tissues via oral administration in humans has not been determined.
- It is a research chemical, not a supplement or drug. It has no FDA approval, no IND status, and no legal basis for marketing as a therapeutic product.
- Cost is $100–$250/month for a compound with no demonstrated human benefit.
Who Might Consider Discussing 5-Amino-1MQ With a Provider
Given the absence of human data, recommending specific populations is not possible based on evidence. Individuals who are interested in the NNMT inhibition concept should be aware that:
- They are essentially self-experimenting with a research chemical
- No provider can offer evidence-based guidance on dosing, duration, or expected outcomes in humans
- Better-studied alternatives exist for every marketed use (obesity, NAD+ support, metabolic health)
- The scientific concept may eventually prove valid in humans, but the compound has not been tested
Questions to Ask a Provider
- Are you aware that no human clinical trials have been published for 5-Amino-1MQ?
- What is the basis for recommending a compound with only mouse data?
- Has oral bioavailability been established for this compound in humans?
- What monitoring would you recommend given the absence of human safety data?
- Are there better-studied alternatives for my specific goal?
- Where is this product sourced, and what quality testing has been performed?
This content is for informational and educational purposes only. It is not intended as, and should not be interpreted as, medical advice. The information provided does not cover all possible uses, precautions, interactions, or adverse effects, and may not reflect the most recent medical research or guidelines. It should not be used as a substitute for the advice of a qualified healthcare professional. Never disregard professional medical advice or delay seeking treatment because of something you have read here. Always speak with your doctor or pharmacist before starting, stopping, or changing any prescribed medication or treatment. If you think you may have a medical emergency, call your doctor or emergency services immediately. GLPbase does not recommend or endorse any specific tests, physicians, products, procedures, or opinions. Use of this information is at your own risk.
Sources & Further Reading
5-Amino-1MQ Direct Research
NNMT Target Validation
- Kraus et al. (2014) — "Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity" — Nature
- Hong et al. (2015) — "Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism" — Trends in Endocrinology & Metabolism
Regulatory
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
